Previous 10 | Next 10 |
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference, Wednesday, February 26, at 2:30 p.m. ET at the Lotte New York Palace, New York, NY ...
Bluebird bio (NASDAQ: BLUE ) initiated with Buy rating and $120 (56% upside) price target at Bank of America. Upgraded to Outperform with a $100 price target at Evercore ISI. Shares up 2% premarket. More news on: bluebird bio, Inc., Centene Corporation, Myovant Sciences Ltd., H...
Quick Take Beam Therapeutics ( BEAM ) intends to raise $100 million from the sale of its common stock, per an amended registration statement . The company is advancing a pre-clinical set of programs for the treatment of various diseases that may possibly be treated via gene editing of a s...
GlaxoSmithKline 's (NYSE: GSK) experimental new cancer drug, belantamab mafodotin, will receive a priority review from the U.S. Food and Drug Administration. The agency's recent decision means belantamab will probably become the first of several drugs to treat multiple myeloma ...
2019 was a good year for the stock market; the S&P 500 provided a return of almost 30% during the year. And some industries performed even better than that. Consider the biotech industry, measured by the SPDR S&P Biotech ETF , which was up by about 32.5% in 2019. Could biotech st...
Bluebird bio (NASDAQ: BLUE ) announces the launch in Germany of ZYNTEGLO (autologous CD34+ cells encoding β A-T87Q -globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β 0 /β...
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEG...
People and institutions that refuse to admit error eventually discredit themselves .”― Jeffrey Tucker Today, we look at CAR-T pioneer bluebird bio ( BLUE ), a name I get a few inquiries on, it seems every month. Our current take on bluebird is provided in the paragraphs be...
Company Overview Bluebird Bio ( BLUE ) is a biotechnology company developing potentially transformative gene and cell therapies for severe genetic diseases and cancer. Bluebird believes that gene therapy for severe genetic diseases has the potential to change the way patients living wit...
Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...